During the upscaling process, Polyrizon and its manufacturing partner successfully transitioned from small-batch laboratory production to a larger-scale, controlled manufacturing run designed to ...

From a modest lab in Israel to an idea potentially able to touch lives around the world, Polyrizon's journey embodies the grit of biotech entrepreneurship. As clinical horizons loom, the company ...

GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and ...

Polyrizon Ltd. ( ($PLRZ) ) has provided an update. On December 2, 2025, Polyrizon Ltd. announced the successful completion of a significant ...

Polyrizon stock is up on new data showing its naloxone hydrogel formulation has stronger and longer-lasting mucosal retention ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 ...

Milestone Pharmaceuticals announced a Commercial Launch Plan investor event, indicating proactive engagement with investors and transparency about its upcoming strategies. The event will detail the ...

The recall of 41,328 bottles is a reminder that even simple treatments must undergo strict microbiological controls.

(Reuters) - Britain's Consort Medical Plc said on Monday it had agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.